Clinical trials: Allergy; Dermatitis
Healthy Volunteer, Atopic Dermatitis
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B).
- Trial name
- AURA-AD (NCT07527923)
- Testing
- REGN20423
- Where
- 7 sites in United States, Belgium
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)
The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with over Moderately subacute and chronic Atopic Dermatitis after inject.
- Trial name
- NCT01927705
- Testing
- FURESTEM-AD Inj.
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis, Atopic
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease
- Trial name
- NCT06436183
- Testing
- Camoteskimab
- Where
- 35 sites in United States, Canada
- Volunteers
- 62 people
- Sponsor
- Apollo Therapeutics Ltd
Atopic Dermatitis
Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis
This study is a single center, randomized, double-blind, Vehicle controlled,, single and multiple dose clinical study.
- Trial name
- NCT06009094
- Testing
- VC005
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical…
- Trial name
- ADhere (NCT04250337)
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 63 sites in United States, Canada and 2 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
- Trial name
- NCT07230483
- Testing
- CM512
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Keymed Biosciences Co.Ltd
Mild to Moderate Atopic Dermatitis
A Controlled Study to Evaluate the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis
Evaluation of safety and clinical efficacy of an active ingredient versus placebo for the treatment of mild to moderate Atopic Dermatitis (AD) adults.
- Trial name
- NCT05057351
- Testing
- Isopentenyltheophylline 0.44% + Glycerin 4.56%, Glycerin 4.56%
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Greenpharma S.A.S.
Psoriasis, Atopic Dermatitis
Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis
Psoriasis is a chronic autoimmune disorder of the skin. In this disease, the inflammatory caspases, cysteine proteases involved in the processing of many proteins, are activated.
- Trial name
- NCT01538342
- Testing
- 3 Biopsies, 2 biopsies, biopsy
- Where
- 3 sites in France
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Atopic Dermatitis
A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect of VC005 Tablets in healthy subjects
- Trial name
- NCT07533851
- Testing
- VC005 Tablets
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
- Trial name
- NCT01228513
- Testing
- ZK245186
- Where
- 16 sites in United States, Japan
- Volunteers
- 263 people
- Sponsor
- Bayer
Dermatitis, Atopic
Effect of Dietary Phospholipids on Atopic Dermatitis
The aim of the study is to investigate the influence of a milk phospholipid enriched dairy product on subjects with atopic dermatitis determining parameters of the immune status, the plasma lipid profile and the skin texture.
- Trial name
- NCT01326520
- Testing
- milk phospholipid, diary product
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- University of Jena
Atopic Dermatitis
Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.
- Trial name
- NCT03018691
- Testing
- OPA-15406
- Where
- 4 sites in Japan
- Volunteers
- 73 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Allergic Contact Dermatitis, Metal Allergy
Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases
The goal of this clinical trial is to collect environmental, bio-humoral, and clinical data derived from patients with allergic contact dermatitis (ACD) and systemic metal allergic syndromes related to the exposure to heavy…
- Conditions
- Allergic Contact Dermatitis, Metal Allergy, Food Allergy, Nickel Sensitivity
- Trial name
- MATRIOSKA (NCT06529913)
- Testing
- Collection of environmental, biological, and clinical data
- Where
- 2 sites in Italy
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Atopic Eczema
Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema
The aim of the study is an intra-individual comparison of skin conditions in addition to a patient based assessment of product appearance in the topical treatment of atopic eczema.
- Trial name
- NCT01119313
- Testing
- LAS 41002, Active
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic
Distribution of Tacrolimus in Skin, Atopic Dermatitis
This study was designed to further increase the understanding of the pharmacokinetics of tacrolimus in the affected skin of atopic dermatitis patients following repeated topical application of tacrolimus ointment 0.1%.
- Trial name
- NCT00534508
- Testing
- Tacrolimus Ointment 0.1%
- Where
- Ireland
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 injection in the treatment of patients with moderate to severe atopic dermatitis.
- Trial name
- NCT06383468
- Testing
- AK120
- Where
- 59 sites in China
- Volunteers
- 420 people
- Sponsor
- Akeso
Atopic Dermatitis
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Upadacitinib is an approved drug for treating AD.
- Trial name
- REACH-AD (NCT06421740)
- Where
- 38 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)
This is a 3-part study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MK-8226 in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT01732510
- Testing
- MK-8226
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC
Atopic Dermatitis
A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.
- Trial name
- NCT03496974
- Testing
- Bermekimab Monoclonal Antibody 200 mg, Bermekimab Monoclonal Antibody 400 mg
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis (AD)
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
- Trial name
- NCT07544862
- Testing
- Stapokibart
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.